A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViSci Ltd.
• Treatments: Latanoprost; Ophthalmic Solutions; Tetrahydrozoline

Criteria

Inclusion Criteria:

• Age > 18

• Open angle glaucoma or Ocular Hypertension

Exclusion Criteria:

• uncontrolled medical conditions

• wearing of contact lenses